Jagsonpal Pharmaceuticals completes 85% stake acquisition in Aequitas Healthcare

1 min read Updated on 17 Jul 2026, 05:44 PM

Reviewed by

Riya DScanX News Team

AI Summary

Jagsonpal Pharmaceuticals Ltd completed the acquisition of an 85% equity stake in Aequitas Healthcare Private Limited on July 17, 2026. The transaction follows previous disclosures made on June 29, July 7, and July 8, 2026.

*this image is generated using AI for illustrative purposes only.

Jagsonpal Pharmaceuticals Ltd has successfully completed the acquisition of an 85% equity stake in Aequitas Healthcare Private Limited. The transaction, finalized on July 17, 2026, marks the conclusion of the acquisition process that was initially proposed to the stock exchanges last month.

The company had previously intimated the exchanges regarding the proposed acquisition on June 29, 2026. Subsequent updates regarding the progress of the deal were provided on July 7, 2026, and July 8, 2026. With the latest disclosure, Jagsonpal Pharmaceuticals Ltd confirmed that the purchase of the majority stake has been fully executed.

Transaction Details

The acquisition involves the purchase of an 85% equity shareholding in Aequitas Healthcare Private Limited. This strategic move expands Jagsonpal Pharmaceuticals Ltd's portfolio through the addition of a new entity under its corporate structure.

Entity	Stake Acquired	Completion Date
Aequitas Healthcare Private Limited	85%	July 17, 2026

Regulatory Disclosures

The disclosure was made to the BSE Ltd and the National Stock Exchange of India Ltd in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was submitted by Pratham Rawal, the Company Secretary & Compliance Officer of Jagsonpal Pharmaceuticals Ltd.

Historical Stock Returns for Jagsonpal Pharmaceuticals

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+2.87%	+3.80%	+0.05%	+41.41%	-21.26%	+225.11%

How will Jagsonpal Pharmaceuticals integrate Aequitas Healthcare's product portfolio into its existing operations?

What is the anticipated financial impact of this acquisition on Jagsonpal's revenue and profitability for the current fiscal year?

Are there any planned management changes or strategic shifts at Aequitas Healthcare following the acquisition?

Read Next Article

Jagsonpal Pharmaceuticals acquires 77.21% stake in Aequitas Healthcare

0 min read Updated on 08 Jul 2026, 06:36 PM

Reviewed by

Naman SScanX News Team

Add as a preferred
source on Google

AI Summary

Jagsonpal Pharmaceuticals Ltd has increased its acquisition of Aequitas Healthcare Private Limited to 77.21%, confirming the entity as a subsidiary. The transaction follows a June 29, 2026 proposal to buy an 85% stake, with the remaining shares yet to be acquired.

*this image is generated using AI for illustrative purposes only.

Jagsonpal Pharmaceuticals Ltd has acquired a 77.21% equity stake in Aequitas Healthcare Private Limited, increasing its holding from the previously reported 69.77%. This transaction confirms Aequitas Healthcare Private Limited as a subsidiary of the Jagsonpal Pharmaceuticals group, strengthening the company's market position.

The acquisition follows a proposal dated June 29, 2026, to purchase an 85% stake in the target entity. While the company has now secured 77.21% of the equity, the remaining portion of the proposed 85% stake is yet to be acquired. The disclosure was made to the stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Acquisition Details

The company completed the purchase of 77.21% of the equity stake out of the 85% proposed. Consequently, Aequitas Healthcare Private Limited has become a subsidiary company within the Jagsonpal Pharmaceuticals group. The remaining portion of the proposed 85% stake is yet to be acquired.